Becton Dickinson and Company (NYSE:BDX) — Market Cap & Net Worth
Market Cap & Net Worth: Becton Dickinson and Company (BDX)
Becton Dickinson and Company (NYSE:BDX) has a market capitalization of $48.93 Billion ($48.93 Billion) as of September 17, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #555 globally and #278 in its home market, demonstrating a 0.64% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Becton Dickinson and Company's stock price $185.92 by its total outstanding shares 272386800 (272.39 Million). Also see Becton Dickinson and Company (BDX) total assets for a full breakdown of the balance sheet.
Becton Dickinson and Company Market Cap History: 2015 to 2026
Becton Dickinson and Company's market capitalization history from 2015 to 2026. Data shows growth from $36.16 Billion to $50.64 Billion (4.09% CAGR). Also see BDX cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Becton Dickinson and Company is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
S&P 500 Index
GSPC
|
$62.85 Trillion | 0.13% | #215 of 503 |
Weight: Becton Dickinson and Company's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Becton Dickinson and Company Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Becton Dickinson and Company's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Becton Dickinson and Company (BDX) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
2.42x
Becton Dickinson and Company's market cap is 2.42 times its annual revenue
Latest Price to Earnings (P/E) Ratio
31.50x
Becton Dickinson and Company's market cap is 31.50 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $39.50 Billion | $12.48 Billion | $976.00 Million | 3.16x | 40.47x |
| 2017 | $51.84 Billion | $12.09 Billion | $1.10 Billion | 4.29x | 47.12x |
| 2018 | $55.27 Billion | $15.98 Billion | $311.00 Million | 3.46x | 177.70x |
| 2019 | $67.54 Billion | $17.29 Billion | $1.23 Billion | 3.91x | 54.77x |
| 2020 | $62.97 Billion | $16.07 Billion | $874.00 Million | 3.92x | 72.05x |
| 2021 | $64.16 Billion | $19.13 Billion | $2.09 Billion | 3.35x | 30.67x |
| 2022 | $67.42 Billion | $18.87 Billion | $1.78 Billion | 3.57x | 37.90x |
| 2023 | $65.62 Billion | $19.37 Billion | $1.48 Billion | 3.39x | 44.22x |
| 2024 | $61.80 Billion | $20.18 Billion | $1.71 Billion | 3.06x | 36.24x |
| 2025 | $52.86 Billion | $21.84 Billion | $1.68 Billion | 2.42x | 31.50x |
Competitor Companies of BDX by Market Capitalization
Companies near Becton Dickinson and Company in the global market cap rankings as of September 17, 2026. Review tangible net worth ratio of Becton Dickinson and Company to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Becton Dickinson and Company by market ranking:
- Intuitive Surgical Inc (NASDAQ:ISRG): Ranked #176 globally with a market cap of $135.13 Billion USD.
- EssilorLuxottica S. A. (PA:EL): Ranked #354 globally with a market cap of $78.17 Billion USD ( €66.86 Billion EUR).
- Alcon AG (SW:ALC): Ranked #895 globally with a market cap of $30.03 Billion USD ( CHF23.75 Billion CHF).
- Medline Inc. Class A Common Stock (NASDAQ:MDLN): Ranked #947 globally with a market cap of $28.17 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #176 | Intuitive Surgical Inc | NASDAQ:ISRG | $135.13 Billion | $377.16 |
| #354 | EssilorLuxottica S. A. | PA:EL | $78.17 Billion | €144.40 |
| #895 | Alcon AG | SW:ALC | $30.03 Billion | CHF55.18 |
| #947 | Medline Inc. Class A Common Stock | NASDAQ:MDLN | $28.17 Billion | $32.11 |
Becton Dickinson and Company Historical Marketcap From 2015 to 2026
Between 2015 and today, Becton Dickinson and Company's market cap moved from $36.16 Billion to $ 50.64 Billion, with a yearly change of 4.09%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $50.64 Billion | -4.20% |
| 2025 | $52.86 Billion | -14.46% |
| 2024 | $61.80 Billion | -5.82% |
| 2023 | $65.62 Billion | -2.67% |
| 2022 | $67.42 Billion | +5.08% |
| 2021 | $64.16 Billion | +1.88% |
| 2020 | $62.97 Billion | -6.75% |
| 2019 | $67.54 Billion | +22.20% |
| 2018 | $55.27 Billion | +6.61% |
| 2017 | $51.84 Billion | +31.24% |
| 2016 | $39.50 Billion | +9.22% |
| 2015 | $36.16 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Becton Dickinson and Company was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $48.93 Billion USD |
| MoneyControl | $48.93 Billion USD |
| MarketWatch | $48.93 Billion USD |
| marketcap.company | $48.93 Billion USD |
| Reuters | $48.93 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segme… Read more